ACC House Call: Breaking Down Vericiguat in VICTORIA

March 28, 2020
Kevin Kunzmann

A heart failure and transplant cardiologist assesses the new study findings.

New findings from the phase 3 Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction (VICTORIA) trial showed the investigative therapy was associated with significantly reduced risk of hospitalization or death due to heart failure in high-risk patients with heart failure and reduced ejection fraction (HFrEF).

The findings, presented virtually by Paul W. Armstrong, MD, during the ACC.20 Together with Word Congress of Cardiology (ACC/WCC) Scientific Sessions on Saturday morning, showed a clinically meaningful benefit for an older, high-risk patient population which currently has limited therapy options.

The interpretation of the VICTORIA data and how it influences heart failure care goes beyond just clinical benefit or reduced morbidity/mortality risk, though. In a special edition House Call video interview with HCPLive®, Radha Gopalan, MD, a heart failure and transplant cardiologist at Banner — University Medicine Heart Institute, discussed the VICTORIA findings as they were published on The New England Journal of Medicine.

Gopalan also discussed the observed HFrEF patient population, the secondary benefits of a therapy such as vericiguat, and what he’d like to see from follow-up or extension assessments of VICTORIA.